Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

PharmacoEconomics

Showing results (11-20 of 3,924) with videos related to

Pageof 393
Sort By:
Pharmacoeconomics|November 1, 2015
Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?Livio Garattini, Anna Padula, Milene Rangel Da Costa
Pharmacoeconomics|November 9, 2015
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific AdaptationMonika Wagner, Hanane Khoury, Jacob Willet, et al.
Pharmacoeconomics|June 11, 2016
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple SclerosisMatthijs Versteegh
Pharmacoeconomics|April 27, 2016
Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3Ron D Hays, Dennis A Revicki, David Feeny, et al.
Pharmacoeconomics|November 28, 2015
What Can We Expect from Value-Based Funding of Medicines? A Retrospective StudyAnthony Harris, Jing Jing Li, Karen Yong
Pharmacoeconomics|March 12, 2016
Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT TrialLars Oddershede, Simon Walker, Wolfgang Stöhr, et al.
Pharmacoeconomics|March 27, 2013
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statementDon Husereau, Michael Drummond, Stavros Petrou, et al.
Pharmacoeconomics|March 27, 2013
A systematic review of utility values for chemotherapy-related adverse eventsFatiha H Shabaruddin, Li-Chia Chen, Rachel A Elliott, et al.
Pharmacoeconomics|March 21, 2013
Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different agesLisa A Prosser, Katherine Payne, Donna Rusinak, et al.
Pharmacoeconomics|December 23, 2015
Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects ModelsWilliam H Crown
Pageof 393

Showing results (11-20 of 3,924) with videos related to

Sort By:
Pageof 393
Pharmacoeconomics|November 1, 2015
Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?Livio Garattini, Anna Padula, Milene Rangel Da Costa
Pharmacoeconomics|November 9, 2015
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific AdaptationMonika Wagner, Hanane Khoury, Jacob Willet, et al.
Pharmacoeconomics|June 11, 2016
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple SclerosisMatthijs Versteegh
Pharmacoeconomics|April 27, 2016
Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3Ron D Hays, Dennis A Revicki, David Feeny, et al.
Pharmacoeconomics|November 28, 2015
What Can We Expect from Value-Based Funding of Medicines? A Retrospective StudyAnthony Harris, Jing Jing Li, Karen Yong
Pharmacoeconomics|March 12, 2016
Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT TrialLars Oddershede, Simon Walker, Wolfgang Stöhr, et al.
Pharmacoeconomics|March 27, 2013
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statementDon Husereau, Michael Drummond, Stavros Petrou, et al.
Pharmacoeconomics|March 27, 2013
A systematic review of utility values for chemotherapy-related adverse eventsFatiha H Shabaruddin, Li-Chia Chen, Rachel A Elliott, et al.
Pharmacoeconomics|March 21, 2013
Using a discrete choice experiment to elicit time trade-off and willingness-to-pay amounts for influenza health-related quality of life at different agesLisa A Prosser, Katherine Payne, Donna Rusinak, et al.
Pharmacoeconomics|December 23, 2015
Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects ModelsWilliam H Crown
Pageof 393